Archivos de bronconeumologia · 2026
Twenty Years of Respiratory Intermediate Care: Clinical Outcomes, Safety Indicators, and Resource Utilization in a Respiratory Intermediate Care Unit.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heili-Frades Sarah, Del Pilar Carballosa María, de Los Ángeles Zambrano María, Fernández Ormaechea Itziar, López Chang Carlos, Morante Tinoco María Mercedes, Pelicano Vizuete Sandra, Rodríguez-Nieto María Jesús, Peces-Barba Romero Germán, Del Pozo Victoria, Naya-Prieto Alba
Аннотация
BACKGROUND: Respiratory Intermediate Care Units (RICUs) are specialized units between conventional hospitalization and intensive care units (ICU), designed to manage patients with acute respiratory failure who require advanced respiratory support and monitoring, but do not necessarily require invasive mechanical ventilation (IMV).
OBJECTIVE: To describe the clinical outcomes, safety indicators, and estimated financial impact and resource utilization of a RICU over a 20-year period.
METHODS: Retrospective study (2003-2023) of all patients admitted to the RICU of a tertiary level hospital in Spain between January 2003 and December 2023. Analysed activities include: non-invasive mechanical ventilation (NIMV), high-flow oxygen therapy (HFOT), weaning from IMV, and interventional procedures. Primary outcomes included mortality, intubation rate, and length of stay (LOS). Financial impact was estimated by comparing the observed RICU costs with a theoretical ICU scenario.
RESULTS: Seven thousand six hundred fifty-four patients were included (mean age 67±14 years, 62% male). The main diagnoses were: COVID-19 pneumonia (30.6%), chronic obstructive pulmonary disease exacerbation (28.7%), and severe pneumonia (22.2%). Additionally, 18.3% were IMV weaning admissions. Overall mortality was 8.4%, and the intubation rate was 12.1%. Among the patients admitted for weaning, survival reached 91.8%. The mean LOS was 6.9 days. Financial impact assessment estimated an average daily cost of €587 for RICU care compared with €940 for the theoretical ICU scenario, corresponding to an estimated annual difference of €485,000.
CONCLUSIONS: Over a 20-year period, this RICU provided specialized care for a large cohort of patients with acute respiratory failure, achieving favourable clinical outcomes with a lower estimated resource utilisation and costs.
OBJECTIVE: To describe the clinical outcomes, safety indicators, and estimated financial impact and resource utilization of a RICU over a 20-year period.
METHODS: Retrospective study (2003-2023) of all patients admitted to the RICU of a tertiary level hospital in Spain between January 2003 and December 2023. Analysed activities include: non-invasive mechanical ventilation (NIMV), high-flow oxygen therapy (HFOT), weaning from IMV, and interventional procedures. Primary outcomes included mortality, intubation rate, and length of stay (LOS). Financial impact was estimated by comparing the observed RICU costs with a theoretical ICU scenario.
RESULTS: Seven thousand six hundred fifty-four patients were included (mean age 67±14 years, 62% male). The main diagnoses were: COVID-19 pneumonia (30.6%), chronic obstructive pulmonary disease exacerbation (28.7%), and severe pneumonia (22.2%). Additionally, 18.3% were IMV weaning admissions. Overall mortality was 8.4%, and the intubation rate was 12.1%. Among the patients admitted for weaning, survival reached 91.8%. The mean LOS was 6.9 days. Financial impact assessment estimated an average daily cost of €587 for RICU care compared with €940 for the theoretical ICU scenario, corresponding to an estimated annual difference of €485,000.
CONCLUSIONS: Over a 20-year period, this RICU provided specialized care for a large cohort of patients with acute respiratory failure, achieving favourable clinical outcomes with a lower estimated resource utilisation and costs.